Skip to main content
2024 Guide to Patient Support Services

UroGen Pharma

2024 PSS Guide

UroGen Pharma UroGen Support

UroGen Pharma offers the UroGen Support program to assist patients while taking Jelmyto (Table). This program makes the access, reimbursement, and coordination process as simple as possible for you and your patients by providing support through territory business managers, field reimbursement managers, and clinical nurse educators.

UroGen Support Copay Program

Patients with commercial health insurance may be eligible to receive Jelmyto for as little as $50 per dose with a maximum benefit of $4000 per dose up to $13,800 per year.

To enroll your patient in the UroGen Support Copay Program, visit UroGen Support Copay Program.

UroGen Support Patient Assistance Program

Uninsured patients may be able to receive Jelmyto through the UroGen Support Patient Assistance Program.

To enroll your patient in the UroGen Support Patient Assistance Program, visit UroGen Support Patient Assistance Program.

TABLE UroGen Pharma Oncology Drug

Drug
Indication
Patient support programs

Drug
Jelmyto (mitomycin)
Indication
Treatment of adults with low-grade upper tract urothelial cancer
Patient support program